Tarsus Pharmaceuticals is attempting to raise $86 million through an initial public offering, Nasdaq reports.
Tarsus is a late-stage biopharmaceutical company focused on developing therapies for ophthalmology conditions.
Tarsus' lead pipeline candidate, TP-03, is attempting to treat Demodex blepharitis. This treatment has completed four phase 2 trials to date. It expects to launch a phase 2b/3 trial in September.
Tarsus was founded in 2016.